Related Experiment Video

Updated: May 29, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond

Susana Banerjee1, Stan Kaye

  • 1Gynaecology Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. susana.banerjee@rmh.nhs.uk

Current Oncology Reports
|September 14, 2011
PubMed

Insights

Poly(ADP-ribose)polymerase (PARP) inhibitors show promise for BRCA-mutated cancers. Further research may expand their use to other cancer types, including ovarian and endometrial cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose)polymerase (PARP) inhibitors are a novel therapeutic strategy.
  • This approach leverages synthetic lethality to target DNA repair defects in cancer cells.
  • BRCA1/BRCA2 mutations are key targets for PARP inhibition.

Purpose of the Study:

  • To review the clinical development of PARP inhibitors in ovarian cancer.
  • To explore the potential of PARP inhibitors in other cancer types, such as sporadic high-grade serous ovarian and endometrial cancers.
  • To identify challenges hindering the full realization of PARP inhibitor efficacy.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of synthetic lethality principles in cancer therapy.
  • Discussion of emerging applications and challenges.

Main Results:

  • PARP inhibitors demonstrate significant efficacy in BRCA mutation-associated ovarian and breast cancers.
  • Evidence suggests potential efficacy in sporadic high-grade serous ovarian cancers.
  • Broader applications in other malignancies, including endometrial cancer, are under investigation.

Conclusions:

  • PARP inhibitors are a promising targeted therapy for specific cancer types.
  • Expanding the use of PARP inhibitors requires addressing current clinical and therapeutic challenges.
  • Further research is crucial to optimize PARP inhibitor treatment strategies.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...